1. Home
  2. MNTS vs CGTX Comparison

MNTS vs CGTX Comparison

Compare MNTS & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Momentus Inc.

MNTS

Momentus Inc.

HOLD

Current Price

$2.15

Market Cap

74.2M

Sector

Industrials

ML Signal

HOLD

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$0.72

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MNTS
CGTX
Founded
2017
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
74.2M
79.6M
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
MNTS
CGTX
Price
$2.15
$0.72
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
★ $3.33
AVG Volume (30 Days)
★ 555.6K
473.0K
Earning Date
11-19-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 62.79
EPS
N/A
★ N/A
Revenue
★ $1,110,000.00
N/A
Revenue This Year
$660.36
N/A
Revenue Next Year
$42.18
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$0.44
$0.55
52 Week High
$22.20
$1.83

Technical Indicators

Market Signals
Indicator
MNTS
CGTX
Relative Strength Index (RSI) 19.25 28.18
Support Level N/A $0.55
Resistance Level $4.44 $1.18
Average True Range (ATR) 0.22 0.06
MACD -0.08 -0.01
Stochastic Oscillator 5.89 19.54

Price Performance

Historical Comparison
MNTS
CGTX

About MNTS Momentus Inc.

Momentus Inc is a U.S.-based commercial space company engaged in providing satellites, satellite buses, and in-space infrastructure services. The company offers space transportation, hosted payload, and in-orbit servicing solutions, including last-mile satellite delivery, refueling, inspection, maintenance, and debris removal. It also develops satellite technologies such as solar arrays and propulsion systems, and provides production and operation of small satellites for government, defense, and commercial customers.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: